Treat Action Group 2023 Pipeline Report

resisttb
Apr 25, 2024
1 min read

Their annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). View the full report here.

Recent Posts

See All

TB Experts Rally Around New, Shortened TB Treatments

A regional training session for 20 countries has been successfully completed in Lima, Peru convened by PeerLNC, a global knowledge hub...

New Initiative Expands Access to Life Saving Drug-Resistant Tuberculosis Treatment

With the new $7.3 million Unitaid investment, Partners In Health (PIH) is beginning a new initiative to improve care and quality of life...

Open letter: Experts call for urgent expansion of Pretomanid label

Despite trials like TB-PRACTECAL displaying the efficacy of pretomanid in the expanded BPaLM regimen, the EMA only approved for the BPaL...

Comments